Skip to main content
Fig. 2 | Immunity & Ageing

Fig. 2

From: An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Fig. 2

IL-6 serum concentration in COVID-19 patients before and 48 h after the treatment with itolizumab. a Individual behavior of IL-6 values in the patients. b Kinetic of the mean of IL-6 levels in the three groups of patients. c Magnitude of change of IL-6 concentration 48 h after the administration of the first itolizumab dose in COVID 19 patients with pre-treatment levels higher than 28.3 pg/mL and lower than 28.3 pg/mL. D0: Before treatment with itolizumab; 48 h: 48 h after the treatment

Back to article page
\